<DOC>
	<DOCNO>NCT00005871</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether nitrocamptothecin effective fluorouracil pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness nitrocamptothecin fluorouracil treat patient recurrent refractory pancreatic cancer treat previously gemcitabine .</brief_summary>
	<brief_title>Nitrocamptothecin Fluorouracil Treating Patients With Recurrent Refractory Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient recurrent refractory pancreatic cancer treatment nitrocamptothecin versus fluorouracil . II . Compare clinical benefit objective response rate treatment regimens patient . III . Compare evaluate time treatment failure patient treatment regimen . IV . Compare toxicities treatment regimens patient . OUTLINE : This randomize , open label , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive nitrocamptothecin orally day 1-5 . Arm II : Patients receive fluorouracil IV 30 minute day 1 . Treatment repeat weekly 8 course absence disease progression unacceptable toxicity . Patients tumor regression stabilization may receive additional course treatment . Patients disease progression unacceptable toxicity may crossover alternate treatment arm . Patients follow every 3 month one year . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study within 15 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent refractory adenocarcinoma pancreas Must receive prior gemcitabine progress PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 50100 % Life expectancy : At least 2 month Hematopoietic : Granulocyte count great 1,500/mm3 Hemoglobin least 9 g/dL Platelet count great 100,000/mm3 Hepatic : SGOT SGPT great 3 time upper limit normal ( ULN ) ( great 5 time ULN tumor involve liver ) Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 2 week since prior gemcitabine recover No prior chemotherapy except gemcitabine No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid hormone Radiotherapy : No concurrent radiotherapy Surgery : At least 2 week since prior major surgery No major surgery within 8 week follow initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>